Emerging treatment option and strategies for inflammatory bowel disease: the state of the art

09:10-09:30

Guangdong Hall I

Leading Forum The growing era of inflammatory bowel disease

Speaker

(BA03) Risankizumab therapy induces improvements in endoscopic endpoints in patients with moderate-to-severe Crohn’s disease: results from two phase 3 studies

(BA03) Risankizumab therapy induces improvements in endoscopic endpoints in patients with moderate-to-severe Crohn’s disease: results from two phase 3 studies

11:30-11:45

Guangdong Hall I

COVID-19 Forum COVID-19: experience is the record of mistakes

Speaker

13:30-15:30

Guangdong Hall I

Asian Forum I Loss of response to current IBD treatment

Chair

16:00-18:00

Guangdong Hall III

Clinical Forum I Cutting-edge forum on IBD therapies

Chair

Panel discussion

13:10-13:20

Guangdong Hall I

Next target of IBD in Asia

Discussant

CD跨膜和黏膜愈合：如何评估和达成

Transmural and mucosal healing of Crohn's disease: how to evaluate and achieve?

13:40-13:55

Guangdong Hall I

中华医学会消化病学会IBD学组2021年会

2021 Annual Conference of Chinese Society of Inflammatory Bowel Disease

Speaker